Effect of Route of Administration of Human Recombinant Factor VIII on Its Immunogenicity in Hemophilia A Mice
- 1 December 2009
- journal article
- research article
- Published by Elsevier BV in Journal of Pharmaceutical Sciences
- Vol. 98 (12), 4480-4484
- https://doi.org/10.1002/jps.21765
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Immunogenicity of Therapeutic ProteinsPublished by Wiley ,2010
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A miceJournal of Pharmaceutical Sciences, 2006
- Lower Inhibitor Development in Hemophilia A Mice following Administration of Recombinant Factor VIII-O-Phospho-L-serine ComplexJournal of Biological Chemistry, 2005
- Immunogenicity of therapeutic proteins.Nephrology Dialysis Transplantation, 2003
- Immunogenicity of biological therapeutics: a hierarchy of concerns.2003
- Immunogenicity of therapeutic proteins: Clinical implications and future prospectsClinical Therapeutics, 2002
- Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.2002
- Factor Viii InhibitorsAdvances in experimental medicine and biology, 2001
- Lymphatic Transport of Proteins After Subcutaneous AdministrationJournal of Pharmaceutical Sciences, 2000